PRME — Prime Medicine, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$3.57
-$0.02 (-0.56%)
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ. It is led by Allan Reine M.D., based in 60 First Street, Cambridge, MA, United States, 02141, with about 146 employees. Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Latest reported PRME revenue for 2025-09-30 was $1.2M. Net income was -$50.6M. Revenue was up 9.9% from 2025-06-30 to 2025-09-30. PRME currently screens at market cap $570.8M.
Use this PRME page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRME quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRME SEC filings page. Lician reads the product cache first so this HTML stays unique to Prime Medicine, Inc. Common Stock even when a live quote feed is slow.
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Key Statistics
Market Cap
$570.75M
Volume
1.95M
Previous Close
$3.71
Day Range
$3.44 – $3.66
P/B Ratio
7.44
EPS
-$1.65
Revenue
$2.98M
Net Income
-$195.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-6566.6%
Employees
146
PRME Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.98M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$195.88M | -$198.13M | -$121.82M | -$165.37M |
| EPS (Diluted) | -$1.65 | -$2.18 | -$4.19 | -$14.19 |
Total Assets
$297.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$182.48M
Operating Cash Flow
-$122.86M
Free Cash Flow
$0.00
Prime Medicine, Inc. Common Stock Company Information
- CEO & Director
- Allan Reine M.D.
- Headquarters
- 60 First Street, Cambridge, MA, United States, 02141
- Website
- primemedicine.com
- Phone
- 617 465 0013
- IPO / Founded
- 2022-10-20
- Sector
- Healthcare
- Industry
- Biotechnology